Biotechnology & Immunology New process thermostats for demanding biotech and pharma applications
Lauda, a global leader in constant temperature equipment, introduces its latest product line - the Ultratemp process thermostats, tailored to meet the rigorous demands of biotechnological, biopharmaceutical, and industrial applications.
With heating and cooling outputs of 25 kW, 35 kW, or 50 kW, the Ultratemp devices are engineered to rapidly heat up or cool down large volumes. This capability proves invaluable for typical biotechnological, biopharmaceutical, and other industrial applications with diverse temperature and performance prerequisites.
The Ultratemp thermostats offer precise control over external consuming units within a range of -5°C to 60°C, maintaining a high temperature stability of ±0.5 K. This ensures accurate temperature control in various applications. The water-cooled refrigeration technology minimises heat discharge to the environment, and the use of non-flammable media, such as water or water-glycol, ensures straightforward handling and low operational costs.
These new Ultratemp process thermostats combine robustness with simplicity in operation. Standardised with protection level IP 54, they are
shielded against splash water and are easy to clean, thanks to the high-quality stainless steel housing. Compatible with non-flammable temperature control media, the device is operated through function buttons and a clear LCD. The integrated Ethernet interface allows remote monitoring and control via a control station or PC. Moreover, external components like sensors (e.g., a Pt100 temperature probe) or signal transmitters can be connected.
The bi-frequency power supply (400 V; 3/PE; 50 Hz & 460 V; 3/PE; 60 Hz) equips the Ultratemp process thermostats for worldwide use. Additionally, they are available in an optimised design exclusively for 50 Hz. All variants can operate within an ambient temperature range of -15°C to 50°C.
The Ultratemp process thermostats expand Lauda’s product range, delivering optimal solutions for biotechnological applications with reactor volumes of up to 5,000 litres. Specially designed to meet the demands of the biopharmaceutical industry and its processes, these devices provide the necessary high heating and cooling capacities for extended process times at a constant temperature of 37°C, followed by rapid cooling of the reactor content.
With the introduction of Ultratemp process thermostats, Lauda strengthens its product portfolio, reaffirming its commitment to innovative temperature control solutions that enhance productivity and efficiency in biotechnology, pharmaceuticals, and industry worldwide.
More information online:
ilmt.co/PL/wzRR 62212pr@reply-direct.com Highly consistent collagen fi bre scaffold for 3D cell culture
CollaFibR™ from AMSBIO is a collagen fibre matrix produced using patented dry-spinning technology. This innovative material closely mimics the biomechanical and biochemical properties of natural collagen scaffolds, providing a highly accurate representation of in-vivo conditions.
CollaFibR™ is manufactured on a commercial scale using automated Good Manufacturing Process technology, ensuring high consistency and quality. It caters to various applications in 3D cell culture and tissue engineering, offering physiologically relevant environments for cellular alignment, migration, and elongation.
The user-friendly 12-well plate insert format makes CollaFibR™ scaffolds ideal for both 2D and 3D cell culture applications. Custom scaffolds tailored to specific needs are also available, with control over thicknesses, porosities, and alignment, ensuring batch-to-batch consistency and high cell viability.
With options for fluorescent tagging, CollaFibR™ scaffolds are compatible with various microscopy techniques and come UV sterilised for immediate use. They are degradable with collagenase, facilitating easy cell extraction.
Additionally, CollaFibR™ is offered as short dry-spun 50 μm collagen fibres, enhancing cellular viability, shape fidelity, and biological relevance in bioinks and hydrogels.
CollaFibR™ scaffolds set a new standard for cell culture consistency, driving innovation in areas such as 3D tissue culture, myelination studies, and contract tissue engineering. More information online:
ilmt.co/PL/BXXR
62383pr@reply-direct.com Collaboration aims to develop nanobodies against cancer
ENPICOM, a leading provider of bioinformatics software solutions, announces a strategic partnership with Erasmus Medical Center (MC), a renowned institution in cancer research. The collaboration aims to advance the identifi cation and development of nanobodies against cancer utilising ENPICOM’s immune repertoire data analysis services and software solutions.
Dr Guido Jenster, project lead and Professor of Experimental Urological Oncology at Erasmus MC, expressed confi dence in the collaboration: “We selected ENPICOM to support our project because of their unique software tailored for antibody discovery workfl ows and their ability to integrate seamlessly with our team. By leveraging our collective expertise, we aim to make signifi cant strides in discovering novel cancer therapeutics.” The partnership is supported by funding from the Ministry of Economic Affairs through the PPP Allowance provided by the Top Sector Life Sciences & Health to promote public-private collaborations.
Paul van der Velde, CEO of ENPICOM, shares his enthusiasm: “We are thrilled to collaborate with Erasmus MC, a leader in cancer research, to explore the potential of nanobody-based treatments. Nanobodies offer promising advantages in cancer therapy due to their small size, enhanced tissue penetration, and greater stability.”
Compared to traditional antibodies, nanobodies boast a smaller size, facilitating better tissue penetration and tumour infi ltration. Their longer CDR3 regions enable superior recognition of hidden epitopes, while their single-chain structure enhances stability and ease of production and engineering.
ENPICOM’s IGX Platform specialises in analysing antibody sequencing data to identify a diverse range of developable candidates. The platform seamlessly integrates sequence and experimental assay data, facilitating effi cient cluster, phylogenetic, and display enrichment analyses in a secure and scalable environment. Additionally, the platform enables high-throughput structural modelling of antibodies to pinpoint the most promising candidates for further development.
In addition to the IGX Platform, ENPICOM offers comprehensive immune repertoire sequencing and analysis services in collaboration with Cerba Research. Furthermore, ENPICOM provides on-demand repertoire analysis and custom development to support non-standard R&D initiatives, combining immunology, bioinformatics, and software engineering expertise to tackle challenges related to adaptive immune repertoires.
More information online:
ilmt.co/PL/vz1R 62344pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
